Mahana Therapeutics Digital IBS Therapeutic Selected For Digitalhealth.London Accelerator Program

Mahana Therapeutics, which develops prescription digital therapeutics designed to empower people living with chronic health conditions, was selected for the DigitalHealth.London’s Accelerator program. Mahana’s first product, Mahana IBS, is the world’s first digital therapeutic to receive FDA clearance and CE Mark for the treatment of irritable bowel syndrome (IBS); it provides gut-directed cognitive behavioral therapy (CBT) to adults with IBS. The Accelerator 2022 program selects companies with digital solutions or services that have high potential to meet London’s National Health Service (NHS) and social care challenges.

Up to 10% of the UK population is . . .